Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
Kara L. Davis, Elizabeth Fox, Melinda S. Merchant, Joel M. Reid, Rachel A. Kudgus, Xiaowei Liu, Charles G. Minard, Stephan D. Voss, Stacey L. Berg, Brenda J. Weigel, Crystal L. Mackall
Topics & Concepts
Open labelRefractory (planetary science)NivolumabMedicineLymphomaOncologyClinical trialInternal medicineCancerImmunotherapyMaterials scienceMetallurgyCancer Immunotherapy and BiomarkersCAR-T cell therapy researchNeuroblastoma Research and Treatments